1.
Bioorg Med Chem Lett
; 17(10): 2740-4, 2007 May 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17418567
RESUMO
The biological evaluation of imidazopiperidines as FAS II inhibitors of Mycobacterium tuberculosis growth has been carried out with a view to assessment of potential as lead compounds for the development of a new TB drug. A summary of the hit evaluation and current challenges is described herein.